Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers. Read this story
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers. Read this story
More from CNBC | Respiratory syncytial virus Breaking news GSK plc Science Pfizer Inc Health care industry Pharmaceuticals Biotechnology Biotech and Pharmaceuticals Business business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source